Clinical Trials Logo

Urinary Bladder, Overactive clinical trials

View clinical trials related to Urinary Bladder, Overactive.

Filter by:

NCT ID: NCT01884753 Completed - Clinical trials for Overactive Bladder Syndrome

Correlations of 3D Urethral and Paraurethral Sonographic Findings With Urodynamic Studies, Lower Urinary Tract Symptoms & Sexual Dysfunction in Female Patients With Lower Urinary Tract Symptoms.

Start date: February 2, 2014
Phase:
Study type: Observational [Patient Registry]

The main purpose of this study is to get the urethra and pelvic sonographic imaging by 4D ultrasound examinations, and to correlate the sonographic findings with urodynamic variables, pad weights and LUTS. Besides, the associations of the blood flow of vagina/urethra and sexual dysfunction can be explored.

NCT ID: NCT01876186 Recruiting - Clinical trials for Overactive Bladder Syndrome

Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients

Start date: May 2013
Phase: Phase 4
Study type: Interventional

To investigate whether prolonged period of treatment (6 months) can have a better therapeutic outcome than conventional period (3 months) of antimuscarinics.

NCT ID: NCT01870037 Completed - Overactive Bladder Clinical Trials

Phase 1 Study With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer

OAB
Start date: January 2013
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the safety of a single treatment of hMaxi-K compared to placebo (PBS-20% sucrose) administered by direct bladder wall injections. Two dose levels (16000 µg and 24000 µg; 20 or 30 bladder wall injections, respectively) in females with moderate Overactive Bladder/Detrusor overactivity (OAB/DO) of ≥6 months duration will be evaluated. In each dose level, 6 participants will receive hMaxi-K and 3 will receive placebo.

NCT ID: NCT01868516 Completed - Overactive Bladder Clinical Trials

Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder

Start date: May 2013
Phase: Phase 2
Study type: Interventional

Overactive bladder (OAB) is a syndrome characterized by symptoms of a sudden need to urinate with or without incontinence (leaking). The purpose of this study is to test whether dexmecamylamine is safe and effective compared to placebo for the treatment of symptoms of OAB.

NCT ID: NCT01848366 Active, not recruiting - Overactive Bladder Clinical Trials

Biowave Overactive Bladder Trial

OAB
Start date: May 2013
Phase: N/A
Study type: Interventional

Demonstrate a response to stimulation of the posterior tibial nerve using the Biowave device and a microneedle patch electrode in patients with overactive bladder symptoms. The investigators hypothesize that after at least 6 weekly treatments there will be modest improvements in overactive bladder symptoms trending toward more improvement.

NCT ID: NCT01842685 Recruiting - Overactive Bladder Clinical Trials

Bladder Thermal Distention for Patients With Refractory Overactive Bladder

OAB
Start date: April 2013
Phase: N/A
Study type: Interventional

In this study, the investigators will evaluate the efficacy of Bladder Thermal Distention (BTD) in patients with overactive bladder syndrome who failed previous treatment of anticholinergic drugs. The investigators' hypothesis is that it will improve the storage symptoms.

NCT ID: NCT01837654 Completed - Overactive Detrusor Clinical Trials

Plantarflexion Reduces Urgency and Peak Detrusor Pressure in Patients With Detrusor Overactivity

DO
Start date: June 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to find out whether plantarflexion has an effect on the degree of urinary urgency and on the amplitude of detrusor contraction during filling cystometry in patients with detrusor overactivity (DO).

NCT ID: NCT01833663 Completed - Overactive Bladder Clinical Trials

Effectiveness and Safety Study of Solifenacin Succinate and Solifenacin Succinate + Estrogen to Treat OAB in Postmenopausal Women

OAB
Start date: October 2011
Phase: Phase 4
Study type: Interventional

This study is a multi-site, randomized, opened and parallel-controlled clinical study. The patients up to the inclusion criteria are randomly treated with Solifenacin Succinate Tablets (5mg/d) or Solifenacin Succinate Tablets (5mg/d) + local estrogen for 12 weeks. Before the dosing and at Week 4, 8 and 12 of the dosing, various examinations are made, and various indices are evaluated.

NCT ID: NCT01824420 Completed - Overactive Bladder Clinical Trials

Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome

Start date: March 2013
Phase: Phase 4
Study type: Interventional

To investigate if oxybutynin ER adding on antimuscarinics is more effective than mono-antimuscarinic treatment for patients with refractory OAB

NCT ID: NCT01819168 Completed - Clinical trials for Overactive Bladder Syndrome

Antimuscarinic Treatment for Female Patients With Overactive Bladder Syndrome: Comparison of Daytime and Nighttime Dosing

Start date: March 2013
Phase: N/A
Study type: Observational

The aim of this retrospective study is to analyze if nighttime antimuscarincs may be more effective in treating patients with nocturia.